Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT NASDAQ:ELVN NASDAQ:GPCR NASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AELVNEnliven Therapeutics$21.65-5.9%$19.86$13.30▼$30.03$1.13B0.83302,756 shs900,984 shsGPCRStructure Therapeutics$19.23-1.7%$22.14$13.22▼$47.48$1.12B-1.87834,652 shs1.10 million shsPRTAProthena$6.22-3.3%$6.07$4.32▼$25.42$346.11M0.01803,515 shs730,504 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+3.31%ELVNEnliven Therapeutics-5.87%+8.63%-1.19%+34.72%-13.75%GPCRStructure Therapeutics-1.74%+2.61%-11.30%+3.78%-56.81%PRTAProthena-3.27%-4.60%+22.44%-32.83%-72.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AELVNEnliven Therapeutics2.7988 of 5 stars3.52.00.00.02.54.20.0GPCRStructure Therapeutics2.855 of 5 stars3.53.00.00.03.01.70.6PRTAProthena3.5788 of 5 stars4.24.00.00.01.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AELVNEnliven Therapeutics 3.00Buy$41.2090.30% UpsideGPCRStructure Therapeutics 3.00Buy$76.17296.08% UpsidePRTAProthena 2.33Hold$31.50406.43% UpsideCurrent Analyst Ratings BreakdownLatest PRTA, CALT, GPCR, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.006/23/2025GPCRStructure TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.006/23/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$89.006/20/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral6/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.005/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/APRTAProthena$135.16M2.48N/AN/A$9.05 per share0.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$0.87N/AN/AN/AN/A-16.35%-15.71%8/6/2025 (Estimated)PRTAProthena-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/6/2025 (Estimated)Latest PRTA, CALT, GPCR, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ELVNEnliven Therapeutics-$0.54N/AN/AN/AN/AN/A5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59ELVNEnliven TherapeuticsN/A21.0721.06GPCRStructure TherapeuticsN/A23.2923.29PRTAProthenaN/A9.009.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%ELVNEnliven Therapeutics95.08%GPCRStructure Therapeutics91.78%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%ELVNEnliven Therapeutics25.90%GPCRStructure Therapeutics9.43%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableGPCRStructure Therapeutics13657.34 million51.94 millionOptionablePRTAProthena13053.83 million48.88 millionOptionablePRTA, CALT, GPCR, and ELVN HeadlinesRecent News About These CompaniesProthena (NASDAQ:PRTA) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?July 12, 2025 | marketbeat.comPRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?July 4, 2025 | zacks.comProthena (NASDAQ:PRTA) Stock Price Passes Below 200 Day Moving Average - Should You Sell?July 4, 2025 | marketbeat.comProthena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by AnalystsJune 25, 2025 | marketbeat.comProthena Corp (PRTA) Receives Reiterated Neutral Rating from Cantor Fitzgerald | PRTA Stock NewsJune 20, 2025 | gurufocus.comCantor Fitzgerald Reiterates "Neutral" Rating for Prothena (NASDAQ:PRTA)June 20, 2025 | marketbeat.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 19, 2025 | finance.yahoo.comProthena Announces Corporate RestructuringJune 18, 2025 | finance.yahoo.comProthena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average - Time to Sell?June 18, 2025 | marketbeat.comRoche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)June 17, 2025 | msn.comProthena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | uk.finance.yahoo.comProthena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16, 2025 | businesswire.comPRTA Prothena Corporation plcJune 7, 2025 | seekingalpha.comPiper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial DiscontinuationMay 30, 2025 | msn.comChardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial FailureMay 30, 2025 | msn.comH.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PTMay 30, 2025 | insidermonkey.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 30, 2025 | finance.yahoo.comB of A Securities Downgrades Prothena (PRTA)May 29, 2025 | msn.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 28, 2025 | finance.yahoo.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 28, 2025 | insidermonkey.comAnalysts Offer Insights on Healthcare Companies: Prothena (PRTA) and Bristol-Myers Squibb (BMY)May 28, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTA, CALT, GPCR, and ELVN Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 07/14/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Enliven Therapeutics NASDAQ:ELVN$21.65 -1.35 (-5.87%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$23.00 +1.35 (+6.24%) As of 07/15/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Structure Therapeutics NASDAQ:GPCR$19.23 -0.34 (-1.74%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$19.68 +0.45 (+2.37%) As of 07/15/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Prothena NASDAQ:PRTA$6.22 -0.21 (-3.27%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$6.22 +0.00 (+0.08%) As of 07/15/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
